Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era

Therapeutic activity of mTOR inhibitors in mantle cell lymphoma: Clues but no clear answers

(2014) Anas Younes   Autophagy

p53-dependent inhibition of TrxR1 contributes to the tumor-specific induction of apoptosis by RITA

(2011) Elisabeth Hedström et al.   CELL CYCLE

Targeting mTOR globally in cancer: Thinking beyond rapamycin

(2011) Boris Shor et al.   CELL CYCLE

Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma

(2010) V. V. Leshchenko et al.   BLOOD

microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma

(2010) J.-J. Zhao et al.   BLOOD

Genetic Dissection of the Oncogenic mTOR Pathway Reveals Druggable Addiction to Translational Control via 4EBP-eIF4E

(2010) Andrew C. Hsieh et al.   CANCER CELL

Genomic and Gene Expression Profiling Defines Indolent Forms of Mantle Cell Lymphoma

(2010) V. Fernandez et al.   CANCER RESEARCH

Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer

(2010) E. Kupperman et al.   CANCER RESEARCH

HDM4 is overexpressed in mantle cell lymphoma and its inhibition induces p21 expression and apoptosis

(2010) Mei Liang et al.   MODERN PATHOLOGY

How I treat mantle cell lymphoma

(2009) M. Ghielmini et al.   BLOOD

Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma

(2009) K. Dunleavy et al.   BLOOD

TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas

(2009) K. Honma et al.   BLOOD

Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting

(2009) Antonina V. Kurtova et al.   BLOOD

BAFF-R promotes cell proliferation and survival through interaction with IKKβ and NF-κB/c-Rel in the nucleus of normal and neoplastic B-lymphoid cells

(2009) Lingchen Fu et al.   BLOOD

Bortezomib induces canonical nuclear factor- B activation in multiple myeloma cells

(2009) T. Hideshima et al.   BLOOD

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

(2009) J. W. Friedberg et al.   BLOOD

Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre phase 2 clinical trial

(2009) Owen A. O’Connor et al.   BRITISH JOURNAL OF HAEMATOLOGY

Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma

(2009) Thomas M. Habermann et al.   BRITISH JOURNAL OF HAEMATOLOGY

PI3 Kinase Signals BCR-Dependent Mature B Cell Survival

(2009) Lakshmi Srinivasan et al.   CELL

Phosphatidylinositol 3'-Kinase Catalytic Subunit   Gene Amplification Contributes to the Pathogenesis of Mantle Cell Lymphoma

(2009) A. Psyrri et al.   CLINICAL CANCER RESEARCH

A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies

(2009) O. A. O'Connor et al.   CLINICAL CANCER RESEARCH

Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy

(2009) M. H. Kang et al.   CLINICAL CANCER RESEARCH

Update on Hsp90 Inhibitors in Clinical Trial

(2009) Y. Kim et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype

(2009) A. Mozos et al.   HAEMATOLOGICA

Nuclear cyclin D1: An oncogenic driver in human cancer

(2009) Jong Kyong Kim et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease

(2009) Thomas S. Lin et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

(2009) Georg Hess et al.   JOURNAL OF CLINICAL ONCOLOGY

Protein Profiling of Plasma Membranes Defines Aberrant Signaling Pathways in Mantle Cell Lymphoma

(2009) Robert S. Boyd et al.   MOLECULAR & CELLULAR PROTEOMICS

Proximal events in Wnt signal transduction

(2009) Stephane Angers et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells

(2009) A Prasad et al.   ONCOGENE

ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells

(2009) Q. Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Perifosine: Update on a novel Akt inhibitor

(2009) Joell J. Gills et al.   Current Oncology Reports

Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies

(2008) P. Martin et al.   ANNALS OF ONCOLOGY

Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study

(2008) A. Goy et al.   ANNALS OF ONCOLOGY

Constitutive activation of the Wnt canonical pathway in mantle cell lymphoma

(2008) P. Gelebart et al.   BLOOD

Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma

(2008) J. Dal Col et al.   BLOOD

Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma

(2008) R. W. Chen et al.   BLOOD

Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma

(2008) L. Paoluzzi et al.   BLOOD

Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling

(2008) S. Bea et al.   BLOOD

The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies

(2008) L. Paoluzzi et al.   BLOOD

GeneChip analyses point to novel pathogenetic mechanisms in mantle cell lymphoma

(2008) Inga Vater et al.   BRITISH JOURNAL OF HAEMATOLOGY

Mutations in Fbx4 Inhibit Dimerization of the SCFFbx4 Ligase and Contribute to Cyclin D1 Overexpression in Human Cancer

(2008) Olena Barbash et al.   CANCER CELL

A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies

(2008) D. A. Rizzieri et al.   CLINICAL CANCER RESEARCH

Targeting Hsp90: small-molecule inhibitors and their clinical development

(2008) Tony Taldone et al.   CURRENT OPINION IN PHARMACOLOGY

Mantle cell lymphoma with flow cytometric evidence of clonal plasmacytic differentiation: A case report

(2008) Hina Naushad et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Genomic aberrations in mantle cell lymphoma detected by interphase fluorescence in situ hybridization. Incidence and clinicopathological correlations

(2008) S. Sander et al.   HAEMATOLOGICA

Elevated Levels of Oncogenic Protein Kinase Pim-1 Induce the p53 Pathway in Cultured Cells and Correlate with Increased Mdm2 in Mantle Cell Lymphoma

(2008) Carol Hogan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Lenalidomide for the Treatment of B-Cell Malignancies

(2008) Asher A. Chanan-Khan et al.   JOURNAL OF CLINICAL ONCOLOGY

Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma

(2008) Annina Herrmann et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular genetic characterization reveals new subsets of mantle cell lymphoma

(2008) Emma Flordal Thelander et al.   LEUKEMIA & LYMPHOMA

Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-kappaB pathways

(2008) Edgar Gil Rizzatti et al.   LEUKEMIA & LYMPHOMA

Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma

(2008) David T Yang et al.   Molecular Cancer

Targeting of sonic hedgehog-GLI signaling: a potential strategy to improve therapy for mantle cell lymphoma

(2008) Ganapati V. Hegde et al.   MOLECULAR CANCER THERAPEUTICS

Signal transduction pathways of mantle cell lymphoma: A phosphoproteome-based study

(2008) Daniela Cecconi et al.   PROTEOMICS

Speeding through cell cycle roadblocks: Nuclear cyclin D1-dependent kinase and neoplastic transformation

(2008) Laura L Pontano et al.   Cell Division

A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma

(2007) F. Morschhauser et al.   ANNALS OF ONCOLOGY

Nuclear expression of the non B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma

(2007) S. Ek et al.   BLOOD